ArticleMolecular cytogenetics2025
Rare case of PLAG1::RUNX1 fusion mimicking classical t(8;21): the value of optical genome mapping in acute myeloid leukemia.
Article in Molecular cytogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic pitfalls and molecular insights in a rare RUNX1::TACC1-positive AML with t(8;21)(p11;q22).Journal of hematopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGene fusions define leukemia subtypes, predicting prognosis and guiding treatment. The classical t(8;21)(q22;q22) translocation results in the RUNX1::RUNX1T1 fusion, characteristic of favorable risk acute myeloid leukemia (AML). To date, more than 21 genes have been identified as partners of RUNX1, each associated with a distinct impact on behavior and outcome. Traditional cytogenetic and molecular techniques often fail to detect cryptic or complex rearrangements, resulting in suboptimal risk assessment. This is a relapsed case of t(8;21) AML involving the rare partner gene PLAG1, identified by optical genome mapping. A review of published cases highlights the distinct prognosis of this fusion. CASE PRESENTATION: A 71-year-old female previously diagnosed with AML, developed a cytogenetic clone with t(8;21)(q?12-13;q22) at relapse. FISH showed RUNX1 rearrangement, without RUNX1T1 involvement. RT-MLPA and Next Generation Sequencing showed KMT2A partial tandem duplication and pathogenic variants in ASXL1, PHF6, RUNX1 and SF3B1. Customized FISH probes identified the breakpoint within the region spanning PLAG1, confirmed as a translocation partner by OGM. The patient showed disease refractoriness despite multiple lines of chemotherapy and died 17 months after diagnosis. DISCUSSION AND
conclusionsPLAG1 is a rare translocation partner of RUNX1 in AML, mistaken for classical t(8;21) on conventional karyotyping. The rare reported cases of PLAG1::RUNX1 suggest a distinctly poor prognosis, highlighting the importance of accurate diagnosis and the role of OGM in our practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.